Reports 46,400 tests to clinical customers and 9,500 tests to biopharma customers, an increase of 29% and 16%, respectively. Preliminary unaudited free cash flow was approximately negative $84M for the fourth quarter of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GH:
- Guardant Health names Terilyn Juarez Monroe as chief people officer
- Guardant Health sells 3.387M shares at $26.77 in registered direct offering
- Guardant Health announces tentative date of FDA panel review of Shield test
- Guardant Health initiated with neutral view at Guggenheim, here’s why
- Guardant Health initiated with neutral view at Wolfe Research, here’s why
